Eiger Biopharmaceuticals Inc (EIGR) Forecasted to Post Q4 2019 Earnings of $1.45 Per Share

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Jefferies Financial Group boosted their Q4 2019 earnings per share estimates for shares of Eiger Biopharmaceuticals in a report released on Monday, May 13th. Jefferies Financial Group analyst M. Raycroft now anticipates that the biotechnology company will earn $1.45 per share for the quarter, up from their previous estimate of $1.41. Jefferies Financial Group also issued estimates for Eiger Biopharmaceuticals’ FY2021 earnings at $0.10 EPS and FY2023 earnings at $3.10 EPS.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.05.



A number of other analysts have also weighed in on the stock. Wedbush reiterated a “buy” rating and set a $43.00 target price on shares of Eiger Biopharmaceuticals in a report on Tuesday, March 26th. BidaskClub upgraded shares of Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 22nd. Zacks Investment Research lowered shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 25th. ValuEngine upgraded shares of Eiger Biopharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Finally, Robert W. Baird started coverage on shares of Eiger Biopharmaceuticals in a report on Monday, January 28th. They set an “outperform” rating and a $47.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $31.29.

Eiger Biopharmaceuticals stock opened at $11.20 on Wednesday. The company has a quick ratio of 10.16, a current ratio of 8.16 and a debt-to-equity ratio of 0.62. Eiger Biopharmaceuticals has a 1-year low of $8.40 and a 1-year high of $18.00.

A number of institutional investors and hedge funds have recently modified their holdings of EIGR. RA Capital Management LLC purchased a new stake in Eiger Biopharmaceuticals in the fourth quarter worth about $24,541,000. 683 Capital Management LLC lifted its holdings in Eiger Biopharmaceuticals by 155.1% in the fourth quarter. 683 Capital Management LLC now owns 1,610,529 shares of the biotechnology company’s stock worth $16,363,000 after buying an additional 979,296 shares during the period. BlackRock Inc. lifted its holdings in Eiger Biopharmaceuticals by 108.6% in the fourth quarter. BlackRock Inc. now owns 468,678 shares of the biotechnology company’s stock worth $4,761,000 after buying an additional 244,028 shares during the period. Fosun International Ltd purchased a new stake in Eiger Biopharmaceuticals in the fourth quarter worth about $1,694,000. Finally, Broadfin Capital LLC purchased a new stake in Eiger Biopharmaceuticals in the fourth quarter worth about $1,456,000. Institutional investors and hedge funds own 78.50% of the company’s stock.

In other news, Director Thomas John Dietz bought 5,000 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was bought at an average cost of $11.05 per share, for a total transaction of $55,250.00. Following the completion of the acquisition, the director now owns 15,000 shares in the company, valued at approximately $165,750. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders have bought 7,250 shares of company stock valued at $80,130. 5.80% of the stock is currently owned by company insiders.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

See Also: What does relative strength index mean?

Earnings History and Estimates for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.